Abstract
Prefibrillar oligomers of the β-amyloid peptide (Aβ) are recognized as potential mediators of Alzheimer’s disease (AD) pathophysiology. Deficits in synaptic function, neurotoxicity, and the progression of AD have all been linked to the oligomeric Aβ assemblies rather than to Aβ monomers or to amyloid plaques. However, the molecular sites of Aβ oligomer action have remained largely unknown. Recently, the cellular prion protein (PrPC) has been shown to act as a functional receptor for Aβ oligomers in brain slices. Because PrPC serves as the substrate for Creutzfeldt–Jakob Disease (CJD), these data suggest mechanistic similarities between the two neurodegenerative diseases. Here, we review the importance of Aβ oligomers in AD, commonalities between AD and CJD, and the newly emergent role of PrPC as a receptor for Aβ oligomers.
Similar content being viewed by others
References
Prince M, Jackson J, Ferri CP, Sousa R, Albanese E, Ribeiro WS, Honyashiki M (2009) Alzheimer’s disease international world alzheimer report 2009. In: International AsD (ed), pp 1–96
Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An english translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8:429–431. doi:10.1002/ca.980080612
Price DL, Tanzi RE, Borchelt DR, Sisodia SS (1998) Alzheimer's disease: genetic studies and transgenic models. Annu Rev Genet 32:461–493. doi:10.1146/annurev.genet.32.1.461
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982–985. doi:10.1038/35050116
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408:979–982. doi:10.1038/35050110
Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216–223. doi:S0140-6736(08)61075-2 [pii] 10.1016/S0140-6736(08)61075-2
Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352–357
Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14:837–842. doi:nm1782 [pii] 10.1038/nm1782
Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106–113. doi:S0166-4328(08)00083-1 [pii] 10.1016/j.bbr.2008.02.016
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866–2875
Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535–539
Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79–84
Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796–807
Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24:10191–10200
Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of Abeta(1–42) into globular neurotoxins. Biochemistry 42:12749–12760
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453
Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT (2009) Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1:326–331. doi:10.1038/Nchem.247
Murray MM, Bernstein SL, Nyugen V, Condron MM, Teplow DB, Bowers MT (2009) Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. J Am Chem Soc 131:6316–6317. doi:10.1021/ja8092604
Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. J Biol Chem 284:4749–4753. doi:R800036200 [pii] 10.1074/jbc.R800036200
Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM (2007) Abeta oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 27:7648–7653
Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572:477–492. doi:jphysiol.2005.103754 [pii] 10.1113/jphysiol.2005.103754
Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid {beta}-protein oligomers. Proc Natl Acad Sci USA. doi:0905127106 [pii] 10.1073/pnas.0905127106
Weissmann C, Fischer M, Raeber A, Bueler H, Sailer A, Shmerling D, Rulicke T, Brandner S, Aguzzi A (1996) The role of PrP in pathogenesis of experimental scrapie. Cold Spring Harb Symp Quant Biol 61:511–522
Prusiner SB, Scott MR, DeArmond SJ, Cohen FE (1998) Prion protein biology. Cell 93:337–348. doi:S0092-8674(00)81163-0 [pii]
Collinge J (2001) Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci 24:519–550. doi:10.1146/annurev.neuro.24.1.519 24/1/519 [pii]
Chesebro B (2003) Introduction to the transmissible spongiform encephalopathies or prion diseases. Br Med Bull 66:1–20
Aguzzi A, Polymenidou M (2004) Mammalian prion biology: one century of evolving concepts. Cell 116:313–327. doi:S0092867403010316 [pii]
Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C (1993) Mice devoid of PrP are resistant to scrapie. Cell 73:1339–1347. doi:0092-8674(93)90360-3 [pii]
Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 379:339–343. doi:10.1038/379339a0
Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302:871–874. doi:10.1126/science.1090187 302/5646/871 [pii]
Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308:1435–1439. doi:308/5727/1435 [pii] 10.1126/science.1110837
Winklhofer KF, Tatzelt J, Haass C (2008) The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J 27:336–349. doi:7601930 [pii] 10.1038/sj.emboj.7601930
Alper T, Haig DA, Clarke MC (1966) The exceptionally small size of the scrapie agent. Biochem Biophys Res Commun 22:278–284. doi:0006-291X(66)90478-5 [pii]
Gibbs CJ Jr, Gajdusek DC, Latarjet R (1978) Unusual resistance to ionizing radiation of the viruses of kuru, Creutzfeldt–Jakob disease, and scrapie. Proc Natl Acad Sci USA 75:6268–6270
Bellinger-Kawahara CG, Kempner E, Groth D, Gabizon R, Prusiner SB (1988) Scrapie prion liposomes and rods exhibit target sizes of 55, 000 Da. Virology 164:537–541
Gabizon R, McKinley MP, Prusiner SB (1987) Purified prion proteins and scrapie infectivity copartition into liposomes. Proc Natl Acad Sci USA 84:4017–4021
Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B (2005) The most infectious prion protein particles. Nature 437:257–261. doi:nature03989 [pii] 10.1038/nature03989
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101–112. doi:nrm2101 [pii] 10.1038/nrm2101
Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, Saeki K, Yokoyama T, Itohara S, Onodera T (1999) Prions prevent neuronal cell-line death. Nature 400:225–226. doi:10.1038/22241
McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW, Williams A, Bell JE (2004) Prion protein accumulation and neuroprotection in hypoxic brain damage. Am J Pathol 165:227–235
Shyu WC, Lin SZ, Chiang MF, Ding DC, Li KW, Chen SF, Yang HI, Li H (2005) Overexpression of PrPC by adenovirus-mediated gene targeting reduces ischemic injury in a stroke rat model. J Neurosci 25:8967–8977. doi:25/39/8967 [pii] 10.1523/JNEUROSCI.1115-05.2005
Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, Bassetti CL, Hermann DM (2005) Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. Neurobiol Dis 20:442–449. doi:S0969-9961(05)00113-0 [pii] 10.1016/j.nbd.2005.04.002
Weise J, Sandau R, Schwarting S, Crome O, Wrede A, Schulz-Schaeffer W, Zerr I, Bahr M (2006) Deletion of cellular prion protein results in reduced Akt activation, enhanced postischemic caspase-3 activation, and exacerbation of ischemic brain injury. Stroke 37:1296–1300. doi:01.STR.0000217262.03192.d4 [pii] 10.1161/01.STR.0000217262.03192.d4
Mitteregger G, Vosko M, Krebs B, Xiang W, Kohlmannsperger V, Nolting S, Hamann GF, Kretzschmar HA (2007) The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol 17:174–183. doi:BPA061 [pii] 10.1111/j.1750-3639.2007.00061.x
Westergard L, Christensen HM, Harris DA (2007) The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 1772:629–644. doi:S0925-4439(07)00060-9 [pii] 10.1016/j.bbadis.2007.02.011
Priola SA, Caughey B, Wehrly K, Chesebro B (1995) A 60-kDa prion protein (PrP) with properties of both the normal and scrapie-associated forms of PrP. J Biol Chem 270:3299–3305
Meyer RK, Lustig A, Oesch B, Fatzer R, Zurbriggen A, Vandevelde M (2000) A monomer-dimer equilibrium of a cellular prion protein (PrPC) not observed with recombinant PrP. J Biol Chem 275:38081–38087. doi:10.1074/jbc.M007114200 M007114200 [pii]
Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Kellermann O (2000) Signal transduction through prion protein. Science 289:1925–1928. doi:8827 [pii]
Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, Kellermann O (2003) NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 100:13326–13331. doi:10.1073/pnas.2235648100 2235648100 [pii]
Shmerling D, Hegyi I, Fischer M, Blattler T, Brandner S, Gotz J, Rulicke T, Flechsig E, Cozzio A, von Mering C, Hangartner C, Aguzzi A, Weissmann C (1998) Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93:203–214. doi:S0092-8674(00)81572-X [pii]
Baumann F, Tolnay M, Brabeck C, Pahnke J, Kloz U, Niemann HH, Heikenwalder M, Rulicke T, Burkle A, Aguzzi A (2007) Lethal recessive myelin toxicity of prion protein lacking its central domain. EMBO J 26:538–547. doi:7601510 [pii] 10.1038/sj.emboj.7601510
Li A, Christensen HM, Stewart LR, Roth KA, Chiesa R, Harris DA (2007) Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105–125. EMBO J 26:548–558. doi:7601507 [pii] 10.1038/sj.emboj.7601507
Warwicker J (2000) Modeling a prion protein dimer: predictions for fibril formation. Biochem Biophys Res Commun 278:646–652. doi:10.1006/bbrc.2000.3829 S0006-291X(00)93829-4 [pii]
Rambold AS, Muller V, Ron U, Ben-Tal N, Winklhofer KF, Tatzelt J (2008) Stress-protective signalling of prion protein is corrupted by scrapie prions. EMBO J 27:1974–1984. doi:emboj2008122 [pii] 10.1038/emboj.2008.122
Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ, Haik S, Fociani P, Bugiani O, Tagliavini F (2008) Tauopathy in human and experimental variant Creutzfeldt–Jakob disease. Neurobiol Aging 29:1864–1873. doi:S0197-4580(07)00198-4 [pii] 10.1016/j.neurobiolaging.2007.04.026
Ghetti B, Dlouhy SR, Giaccone G, Bugiani O, Frangione B, Farlow MR, Tagliavini F (1995) Gerstmann–Straussler–Scheinker disease and the Indiana kindred. Brain Pathol 5:61–75
Ghetti B, Tagliavini F, Giaccone G, Bugiani O, Frangione B, Farlow MR, Dlouhy SR (1994) Familial Gerstmann–Straussler–Scheinker disease with neurofibrillary tangles. Mol Neurobiol 8:41–48. doi:10.1007/BF02778006
Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G, Verga L, Farlow MR, Conneally PM, Dlouhy SR, Azzarelli B et al (1989) Gerstmann–Straussler–Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid coexist in an affected family. Neurology 39:1453–1461
Lopes JP, Oliveira CR, Agostinho P (2007) Role of cyclin-dependent kinase 5 in the neurodegenerative process triggered by amyloid-beta and Prion peptides: implications for Alzheimer's disease and Prion-related encephalopathies. Cell Mol Neurobiol 27:943–957. doi:10.1007/s10571-007-9224-3
Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, van Duijn CM, Cruts M, Van Broeckhoven C, Martin JJ, Cras P (2001) Influence of the prion protein and the apolipoprotein E genotype on the Creutzfeldt–Jakob disease phenotype. Neurosci Lett 313:69–72
Krasnianski A, von Ahsen N, Heinemann U, Meissner B, Kretzschmar HA, Armstrong VW, Zerr I (2008) ApoE distribution and family history in genetic prion diseases in Germany. J Mol Neurosci 34:45–50. doi:10.1007/s12031-007-9001-2
Webb TE, Poulter M, Beck J, Uphill J, Adamson G, Campbell T, Linehan J, Powell C, Brandner S, Pal S, Siddique D, Wadsworth JD, Joiner S, Alner K, Petersen C, Hampson S, Rhymes C, Treacy C, Storey E, Geschwind MD, Nemeth AH, Wroe S, Collinge J, Mead S (2008) Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 131:2632–2646. doi:awn202 [pii] 10.1093/brain/awn202
Pickering-Brown SM, Mann DM, Owen F, Ironside JW, de Silva R, Roberts DA, Balderson DJ, Cooper PN (1995) Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt–Jakob disease. Neurosci Lett 187:127–129. doi:0304-3940(95)11353-3 [pii]
Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt–Jakob disease. Brain Res 541:163–166. doi:0006-8993(91)91092-F [pii]
Giorgi A, Di Francesco L, Principe S, Mignogna G, Sennels L, Mancone C, Alonzi T, Sbriccoli M, De Pascalis A, Rappsilber J, Cardone F, Pocchiari M, Maras B, Schinina ME (2009) Proteomic profiling of PrP27–30-enriched preparations extracted from the brain of hamsters with experimental scrapie. Proteomics 9:3802–3814. doi:10.1002/pmic.200900085
Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HN, Turner AJ, Hooper NM (2007) Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 104:11062–11067. doi:0609621104 [pii] 10.1073/pnas.0609621104
Schmitt-Ulms G, Hansen K, Liu J, Cowdrey C, Yang J, DeArmond SJ, Cohen FE, Prusiner SB, Baldwin MA (2004) Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat Biotechnol 22:724–731. doi:10.1038/nbt969 nbt969 [pii]
Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784. doi:313/5794/1781 [pii] 10.1126/science.1131864
Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M (2009) Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA 106:12926–12931. doi:0903200106 [pii] 10.1073/pnas.0903200106
Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, Hofman A, van Duijn CM, Van Broeckhoven C (2003) PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol 53:409–412. doi:10.1002/ana.10507
Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Muller U, Forstl H, Illig T, Kretzschmar H, Kurz A (2004) Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 63:364–366. doi:63/2/364 [pii]
Papassotiropoulos A, Wollmer MA, Aguzzi A, Hock C, Nitsch RM, de Quervain DJ (2005) The prion gene is associated with human long-term memory. Hum Mol Genet 14:2241–2246. doi:ddi228 [pii] 10.1093/hmg/ddi228
Croes EA, Dermaut B, Houwing-Duistermaat JJ, Van den Broeck M, Cruts M, Breteler MM, Hofman A, van Broeckhoven C, van Duijn CM (2003) Early cognitive decline is associated with prion protein codon 129 polymorphism. Ann Neurol 54:275–276. doi:10.1002/ana.10658
Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65:45–53. doi:2007.3 [pii] 10.1001/archneurol.2007.3
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-[bgr] oligomers. Nature 457: 1128-1132. DOI http://www.nature.com/nature/journal/v457/n7233/suppinfo/nature07761_S1.html
Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B, Williamson RA (2004) Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303:1514–1516. doi:10.1126/science.1094273 1094273 [pii]
Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt–Jakob disease. Neurodegene Dis 5:347–354. doi:000121389 [pii] 10.1159/000121389
Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A, Meissner B, Zerr I (2009) Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis. doi:12G39G6736J3K264 [pii] 10.3233/JAD-2009-1110
Oda T, Himeno R, CH D, Chino K, Kurihara T, Nagayoshi T, Kanehisa H, Fukunaga T, Kawakami Y (2007) In vivo behavior of muscle fascicles and tendinous tissues in human tibialis anterior muscle during twitch contraction. J Biomech 40:3114–3120. doi:S0021-9290(07)00144-3 [pii] 10.1016/j.jbiomech.2007.03.023
Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. J Neurosci 28:13805–13814. doi:28/51/13805 [pii] 10.1523/JNEUROSCI.4218-08.2008
Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 24:7707–7717. doi:10.1523/JNEUROSCI.2211-04.2004 24/35/7707 [pii]
Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457:981–989. doi:nature07767 [pii] 10.1038/nature07767
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159–170
Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457:1128–1132. doi:10.1038/nature07761
Acknowledgments
We thank Haakon B. Nygaard, M.D. for providing Fig. 1. S.M.S. is a member of the Kavli Institute for Neuroscience at Yale University. We acknowledge support from the National Institutes of Health, the Falk Medical Research Trust, an anonymous donor, and the Cure Alzheimer’s Fund to S.M.S.
Conflict of interest statement
The authors declare that they have no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gunther, E.C., Strittmatter, S.M. β-amyloid oligomers and cellular prion protein in Alzheimer’s disease. J Mol Med 88, 331–338 (2010). https://doi.org/10.1007/s00109-009-0568-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-009-0568-7